Company Overview
About Neodocs
Neodocs is a Mumbai, India-based healthtech company — backed by Y Combinator (S21) with $2.48 million raised including a $2 million seed round in February 2024 led by Omidyar Network India with YC, 9Unicorns, Gemba Capital, Titan Capital, and 100Unicorns — providing instant at-home diagnostic test kits with proprietary biochemistry test cards that deliver visual color-change results for conditions including urinary tract infections, diabetes monitoring (HbA1c and glucose), kidney function (creatinine, protein), and general wellness panels without requiring any additional hardware beyond a smartphone camera. Founded in 2020, Neodocs has sold 200,000+ test cards used by 4,000+ doctors across India and has partnerships with major pharmaceutical companies including Cipla, Sun Pharma, and AstraZeneca for co-branded diagnostic test distribution.
Business Model & Competitive Advantage
Neodocs' smartphone-based diagnostic platform enables non-invasive point-of-care testing without the laboratory infrastructure typically required for biochemistry analysis: the Neodocs test card contains dried reagent pads that react colorimetrically with urine or other patient samples — the color change pattern indicates the concentration or presence of specific biomarkers. The Neodocs smartphone app uses the phone camera to capture the test card image, applies computer vision calibration algorithms to correct for lighting variations and camera differences, and interprets the color values against reference standards to generate quantitative results (not just positive/negative, but actual numerical values for glucose, creatinine, and other measurable analytes) within 5-10 minutes. The pharmaceutical partnerships (Cipla, Sun Pharma, Bayer, AstraZeneca, Eris Lifesciences) distribute Neodocs test cards through pharmacy channels alongside the chronic disease medications the tests monitor.
Competitive Landscape 2025–2026
In 2025, Neodocs competes in the point-of-care diagnostics, consumer health monitoring, and India at-home testing market with Siemens Healthineers (ETR: SHL, urinalysis strips and analyzers), Abbvie's Abbott Diagnostics (NYSE: ABT, point-of-care testing), and domestic India diagnostic kit manufacturers for diabetes and chronic disease monitoring test distribution. India's 77 million+ diagnosed diabetics (the world's second-largest diabetic population) and estimated 40 million+ UTI cases annually create structural demand for affordable, accessible point-of-care monitoring. Neodocs' pharmaceutical distribution partnerships (riding Cipla and Sun Pharma's pharmacy networks) provide reach into 800,000+ Indian pharmacies that no direct consumer channel could replicate at comparable speed. Omidyar Network India's impact investment thesis aligns with Neodocs' health access mission for India's Tier 2-4 city population. The 2025 strategy focuses on growing the doctor prescription/recommendation channel, expanding the test panel to thyroid and liver function, and building the longitudinal health data platform for chronic disease management.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Neodocs is an emerging player bringing innovative solutions to the Healthcare market.
Frequently Asked Questions
Not So Random Others
Yoneda Labs
Yoneda Labs is a San Francisco-based AI company applying foundation models to automate chemical reaction optimization for drug discovery and pharmaceutical process development — providing chemists wit
Decoda Health
Decoda Health is a San Francisco-based AI healthcare administration platform — backed by Y Combinator (S23) with $4.5 million raised from YC, Amino Capital, Bossa Nova Ventures, Cadenza Ventures, Grap
Fortuna Health
Fortuna Health is a New York City-based healthcare technology company — backed by Y Combinator with $22 million in total funding including an $18 million Series A in July 2025 led by Andreessen Horowi
Brisk
Brisk is a functional beverage brand offering ready-to-drink iced tea and juice drinks, jointly owned by PepsiCo and Unilever under the Lipton brand partnership. Launched in the 1990s, Brisk positione
Altria
Altria Group, Inc. is a Richmond, Virginia-based tobacco and nicotine company — publicly traded on the New York Stock Exchange (NYSE: MO) as an S&P 500 Consumer Staples component — manufacturing and s
Cursor
Cursor is an AI-powered code editor built on Visual Studio Code that integrates advanced language models to provide intelligent code completion, generation, debugging, and refactoring capabilities dir
Compare Neodocs with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Neodocs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Neodocs Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Neodocs vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →